@article{9f03fbae440a427397526a3fef4b73df,
title = "Pediatric Migraine: An Update",
abstract = "This article outlines key features of diagnosis and treatment of migraine in children and adolescents. It emphasizes techniques that can be used by clinicians to optimize history taking in this population, as well as recognition of episodic conditions that may be associated with migraine and present in childhood. Acute treatment strategies include use of over-the-counter analgesics and triptan medications that have been approved by the US Food and Drug Administration for use in children and adolescents. Preventive treatment approach includes lifestyle modifications, behavioral strategies, and consideration of preventive medications with the lowest side effect profiles.",
keywords = "Adolescents, Children, Headache, Migraine, Pediatric",
author = "Kaitlin Greene and Irwin, {Samantha L.} and Gelfand, {Amy A.}",
note = "Funding Information: K. Greene, nothing to disclose. S.L. Irwin, CEO of HeadSoothe, a company that is working to develop a combination nutraceutical for headache. A.A. Gelfand has received consulting fees from Zosano, Eli Lilly, Impax, Theranica, Advanced Clinical, and Impel Neuropharma. She has received honoraria from UpToDate (for authorship) and JAMA Neurology (as an associate editor). She receives grant support from Amgen and research support from eNeura . She receives personal compensation for medical-legal consulting. Her spouse received consulting fees from Biogen (daclizumab) and Alexion (eculizumab), research support from Genentech (ocrevus), service contract support from MedDay, honoraria for editorial work from Dynamed Plus, and personal compensation for medical-legal consulting. This article discusses the unlabeled/investigational use of all listed medications for the treatment of headache in children and adolescents, with the exceptions of almotriptan oral tablets, sumatriptan/naproxen combination tablets, zolmitriptan nasal spray for adolescents 12 to 17 years of age, rizatriptan oral tablets or melts for acute migraine in children 6 years of age and older, as well as topiramate in adolescents 12 to 17 years of age for migraine prevention. Funding Information: K. Greene, nothing to disclose. S.L. Irwin, CEO of HeadSoothe, a company that is working to develop a combination nutraceutical for headache. A.A. Gelfand has received consulting fees from Zosano, Eli Lilly, Impax, Theranica, Advanced Clinical, and Impel Neuropharma. She has received honoraria from UpToDate (for authorship) and JAMA Neurology (as an associate editor). She receives grant support from Amgen and research support from eNeura. She receives personal compensation for medical-legal consulting. Her spouse received consulting fees from Biogen (daclizumab) and Alexion (eculizumab), research support from Genentech (ocrevus), service contract support from MedDay, honoraria for editorial work from Dynamed Plus, and personal compensation for medical-legal consulting. This article discusses the unlabeled/investigational use of all listed medications for the treatment of headache in children and adolescents, with the exceptions of almotriptan oral tablets, sumatriptan/naproxen combination tablets, zolmitriptan nasal spray for adolescents 12 to 17 years of age, rizatriptan oral tablets or melts for acute migraine in children 6 years of age and older, as well as topiramate in adolescents 12 to 17 years of age for migraine prevention. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = nov,
doi = "10.1016/j.ncl.2019.07.009",
language = "English (US)",
volume = "37",
pages = "815--833",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "4",
}